ABT Healthcare · Medical devices · Diagnostics · Global healthcare · Thesis updated July 19, 2026

Devices lead, but debt and Libre timing matter

Q1 Medical Devices sales were $5.539 billion, almost half of reportable segment sales.
Exact Sciences added cancer diagnostics and about $20 billion of new long-term debt.
Nutrition recovered $125 million sequentially in Q2, easing a Q1 volume scare.
Libre growth has cooled to about 8% to 9% without a new reimbursement wave.
U.S. Structural Heart needs a sales fix after management called out execution problems.

01 Running thesis

A stronger mix with new brakes

Abbott is still led by Medical Devices. In Q1 2026, that segment posted $5.539 billion of sales and grew 8.1% excluding foreign exchange. Rhythm Management, Electrophysiology, and Heart Failure grew at double-digit rates. Diabetes Care, which includes FreeStyle Libre continuous glucose monitors, grew 7.4% excluding foreign exchange.

The Exact Sciences deal gives Abbott a new cancer testing business. Cancer Diagnostics added $96 million of sales from the March 23, 2026 acquisition date in Q1. Management also said Cancer Diagnostics grew 13% in the first half of 2026, with more volume expected in the second half from care gap programs.

The worry list is real. Abbott issued about $20 billion of long-term debt to fund Exact Sciences. Libre growth has paused near 8% to 9% while Abbott waits for new insurance and government coverage. U.S. Structural Heart also has a commercial execution problem in the mitral market, and management says the fix will take a couple of quarters.

Finn's view is balanced, not a victory lap. Abbott has several good growth lanes, but the next step depends on timing: CGM reimbursement, Exact Sciences volume, and a U.S. Structural Heart recovery by year-end.

Jul 2026▲Q2 eased the biggest Nutrition worry, with sales up $125 million from Q1 and international pediatric nutrition back to 6.5% growth. The upgrade is limited because Libre growth has plateaued near 8% to 9% and U.S. Structural Heart has execution issues.

Apr 2026▼Abbott closed the Exact Sciences acquisition and added $96 million of Cancer Diagnostics sales from the acquisition date. The same filing showed about $20 billion of new long-term debt and a 7.7% ex-FX Nutrition decline, which raised the risk level.

Feb 2026▲The 2025 Form 10-K confirmed strong Medical Devices growth, with CGM sales of $7.6 billion in 2025. It also made the Exact Sciences deal a central growth pillar, while flagging the planned debt funding.

Oct 2025▲Medical Devices stayed strong through the first nine months of 2025, led by Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. COVID-19 testing became a smaller drag, and Abbott received favorable infant formula litigation rulings.

Jul 2025▲Q2 2025 showed 6.9% total organic sales growth and more than 20% Diabetes Care growth. The shrinking COVID-19 testing headwind made the core business easier to judge.

Apr 2025→Q1 2025 brought no major thesis change. Medical Devices and Diabetes Care kept leading while the expected COVID-19 diagnostics decline continued.

Feb 2025▲Full-year 2024 results showed Medical Devices up 13.7% organically and CGM sales of $6.4 billion. Abbott also added Lingo to the CGM portfolio, widening the possible market.

Oct 2024→Q3 2024 supported the device-led thesis, but Abbott also disclosed another IRS tax dispute for the 2020 tax year. That expanded a risk already tied to income allocation between U.S. and foreign affiliates.

02 Business model

Many healthcare baskets

Abbott makes money by selling healthcare products to hospitals, labs, pharmacies, distributors, governments, and consumers. The company reports four main segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products.

Medical Devices is the biggest segment. Its growth depends on better technology, doctor adoption, insurance coverage, and Abbott's ability to win share from other device makers. FreeStyle Libre is a key example. It can grow faster when more people with diabetes get coverage for continuous glucose monitoring, or CGM, which tracks glucose through a sensor.

Diagnostics sells lab systems, rapid tests, point of care tests, and now cancer tests from Exact Sciences, including Cologuard and Oncotype DX. This business can swing with testing demand. COVID-19 test sales used to be a major tailwind, but that boost has faded.

Nutrition and branded generic drugs add balance. Nutrition sells brands such as Ensure, Glucerna, PediaSure, and Pedialyte. Established Pharmaceuticals sells branded generic drugs in emerging markets. Across the company, profit can be hurt by price controls, rebates, competition, currency moves, and contract losses.

03 Product portfolio

What Abbott sells

Growth engine

FreeStyle Libre and Diabetes Care

Libre is Abbott's continuous glucose monitor for people with diabetes. Growth has cooled near 8% to 9%, but the long-term market is still large if new reimbursement expands access.

Growth engine

Heart and neuromodulation devices

This includes rhythm management, electrophysiology, heart failure, vascular, structural heart, and neuromodulation devices. Electrophysiology and heart failure are strong, while U.S. Structural Heart needs a sales reset.

Option

Cancer Diagnostics

Exact Sciences brought Cologuard and Oncotype DX into Abbott. The bet is that Abbott can build a larger cancer testing platform, including stool tests and future blood tests.

Steady

Core, rapid, molecular, and point of care diagnostics

These tests support hospitals, labs, and clinics. Core Laboratory grew in Q1, while Rapid and Molecular fell 9.6% excluding foreign exchange because the respiratory virus season was weaker.

Steady

Nutrition brands

Ensure, Glucerna, PediaSure, and Pedialyte serve adult and pediatric nutrition markets. Q1 was weak, but Q2 showed a $125 million sequential sales recovery.

Cash cow

Established Pharmaceuticals

This segment sells branded generic drugs in emerging markets. It grew 9.0% excluding foreign exchange in Q1 2026.

Option

Lingo wellness CGM

Lingo uses Abbott's glucose sensor know-how for health and wellness consumers. It is still an option on a broader market beyond diabetes care.

04 Business segments

Q1 sales mix

Medical Devices50%growing fast

Diagnostic Products20%modest

Nutritional Products18%declining

Established Pharmaceutical Products13%growing fast

The mix uses Q1 2026 reportable segment sales from Abbott's Form 10-Q. Medical Devices is the largest piece, while international sales were 61.7% of total net sales in the quarter.

05 Risk factors

What could break the case

Libre reimbursement delay

High impact · Medium odds

Libre growth has slowed to about 8% to 9% while Abbott waits for the next major coverage expansion. If U.S. Type 2 Medicare coverage or international reimbursement takes longer than expected, the CGM growth story could stay slower than bulls want.

We watchMedicare Type 2 CGM coverage decisions and Abbott's reported Diabetes Care growth rate.

U.S. Structural Heart share loss

Medium impact · Medium odds

Management said the U.S. mitral market problem is not price or product. It is commercial execution, which means sales strategy and field performance. Competitors have become tougher, and Abbott expects the fix to take until around year-end.

We watchStructural Heart growth, especially any return to mid-to-high single-digit U.S. growth by Q4.

Exact Sciences debt load

High impact · Medium odds

Abbott funded the Exact Sciences deal mainly with about $20 billion of new long-term debt. That raises financial risk and can limit flexibility if growth slows or interest costs stay high. The deal must create enough cancer diagnostics growth to justify the balance sheet strain.

We watchDebt reduction, interest expense, and Cancer Diagnostics sales growth.

Nutrition recovery fades

Medium impact · Medium odds

Nutrition sales fell 7.7% excluding foreign exchange in Q1 because volumes were lower in both U.S. and international adult and pediatric products. Q2 improved by $125 million sequentially, but the recovery still needs to prove it can last.

We watchPediatric and adult nutrition volume growth, plus the benefit from U.S. WIC contract wins.

IRS tax dispute

Medium impact · Low odds

Abbott has active IRS disputes tied to how income is split between U.S. entities and foreign affiliates for tax years 2017 through 2020. The company says gross unrecognized tax benefits could fall by about $75 million to $1.33 billion within twelve months, but the final outcome is not certain.

We watchUpdates on IRS SNODs for tax years 2017 through 2020 and changes in unrecognized tax benefits.

06 Quick answers

In one breath

What is Abbott Laboratories best known for?

Abbott is best known for medical devices, diagnostics, nutrition products, and branded generic drugs. Its FreeStyle Libre glucose monitor is one of its most important growth products.

Why did Abbott buy Exact Sciences?

Abbott bought Exact Sciences to enter cancer diagnostics in a bigger way. The deal adds Cologuard, Oncotype DX, and a platform that could support future cancer blood tests.

What is the main risk for Abbott stock?

The main risk is that the growth engines do not speed up enough to offset the new debt from Exact Sciences. Watch Libre reimbursement, Cancer Diagnostics volume, and the U.S. Structural Heart turnaround.